BioNTech, Roche Scrap Cancer Vaccine Trial in Blow to New Field

BioNTech SE and Roche Holding AG abandoned a trial of a personalized cancer vaccine, undermining momentum from a rival drugmaker’s recent success. The development is a meaningful setback to vaccine-related hopes in the personalized oncology space, likely weighing on biotech sentiment around similar approaches. Overall read-through is negative for expectations of near-term clinical progress in this program.